Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: A Southwest Oncology Group study

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 298-305

  Smith, H O ^a,h   Jiang, C S ^b   Weiss, G R ^c   Hallum III, A V ^d   Liu, P Y ^b   Robinson III, W R ^e,i   Cheng, P C ^e   Scudder, S A ^f   Markman, M ^g   Alberts, D S ^d  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e TULANE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

ⁱ Harrington Cancer Center   (United States)

Author keywords

Cervical carcinoma; Chemotherapy; Cisplatin; Tirapazamine

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; LORAZEPAM; MANNITOL; ONDANSETRON; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONFIDENCE INTERVAL; CONSTIPATION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DYSPNEA; EMBOLISM; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTESTINE OBSTRUCTION; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MYALGIA; NAUSEA; NEUTROPENIA; PERCEPTION DEAFNESS; PRIORITY JOURNAL; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZINES; UTERINE CERVICAL NEOPLASMS;

EID: 33645338167     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00339.x     Document Type: Article

References (50)

1. Janicek ME Averette HE. Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin 2001 51 92 114.
2. Cancer Facts and Figures 2004. Atlanta, GA American Cancer Society Inc. Available at http://www.cancer.org.
3. Rose PG Eifel PJ. Combined radiation therapy and chemotherapy for carcinoma of the cervix. Cancer J 2001 72 86 94.
4. Perez DA Camel HM Kuskee RR et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20 year experience. Gynecol Oncol 1986 23 127 40.
5. Jampolis S Andras J Fletcher GH. Analysis of sites and causes of failure of irradiation in invasive squamous carcinoma of the intact uterine cervix. Radiology 1975 115 681 5.
6. Komaki R Brickner TH Hanlon AL Owen JB Hanks GE. Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: Patterns of Care Study (PCS). Int J Radiat Oncol Biol Phys 1995 31 973 82.
7. Peters WA III. Barrett RJ Stock RJ et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000 18 1606 13.
8. Smith HO Tiffany MF Qualls CR Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the U.S. - a 24-year population-based study. Gynecol Oncol 2000 78 97 105.
9. Thigpen T Shingleton H Homesley H Lagasse L Blessing J. Cis-dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979 63 1549 55.
10. Thigpen T Shingleton H Homesley H Lagasse L Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981 48 899 903.
11. Bonomi P Blessing JA Stehman FB DiSaia PJ Walton L Major FJ. Randomized trial of three cisplatin dose schedules in squamous cell cancer of the cervix: a Gynecology Oncology Group study. J Clin Oncol 1985 3 1079 85.
12. Thigpen JT Blessing JA DiSaia PJ Fowler WC Jr. Hatch KD. A randomized comparison of a rapid versus prolonged (24 hour) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989 32 198 202.
13. Alberts DS Kronmal R Baker LH et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell carcinoma of the cervix. A Southwest Oncology Group study. J Clin Oncol 1987 5 1791 5.
14. Bonomi P Blessing J Ball H Hanjani P DiSaia PJ. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989 34 357 9.
15. Weiss GR Green S Hannigan EV et al. A phase II trial of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix. Gynecol Oncol 1990 37 354 8.
16. Smith HO Stringer CA Kavanagh JJ Gershenson DM Edwards CL Wharton JT. Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-c, bleomycin, and cisplatin chemotherapy. Gynecol Oncol 1993 48 11 5.
17. Alberts DS Garcia DJ. Salvage chemotherapy in recurrent or refractory squamous cell carcinoma of the uterine cervix. Semin Oncol 1994 21 37S 46S.
18. Bloss JD Blessing JA Behrens BC et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous cell carcinoma of the cervix: a Gynecology Oncology Group study. J Clin Oncol 2002 20 1832 7.
19. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999 59 5863 70.
20. Zeman EM Lemmon MJ Brown JM. Aerobic radiosensitization by SR 4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys 1990 18 125 32.
21. Zeman EM Hirst VK Lemmon MJ Brown JM. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 1988 12 209 18.
22. Laderoute K Wardman P Rauth AM. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233 Biochem Pharmacol 1988 37 1487 95.
23. Biedermann KA Wang J Graham RP Brown JM. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer 1991 63 358 62.
24. Tocher JH Virk NS Edwards DI. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH. Biochem Pharmacol 1990 40 1405 10.
25. Skarsgard LD Skwarchuck MW Vinczan A Chaplin DJ. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells. Br J Cancer 1993 68 681 3.
26. Lloyd RV Duling DR Rumyantseva GV Mason RP Bridson PK. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 1991 40 440 5.
27. Evans JW Yudoh K Delahoussaye YM Brown JM. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 1998 58 2098 101.
28. Wouters BG Delahoussaye YM Evans JW et al. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 2001 61 145 52.
29. Zeman EM Brown JM. Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys 1989 16 967 71.
30. Brown JM Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 1991 20 457 61.
31. Zeman EM Brown JM. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications. Int J Radiat Biol 1991 59 117 31.
32. Brown JM Lemmon MJ. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol 1991 1 151 6.
33. Brown JM Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990 50 7745 9.
34. Dorie MJ Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993 53 4633 6.
35. Dabholkar M Vionnett J Bostick-Bruton F Yu JJ Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994 94 703 8.
36. Weiss GR Liu PY Alberts DS et al. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-a in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. Gynecol Oncol 1998 71 386 90.
37. Johnson CA Kilpatrick D von Roemeling R et al. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 1997 15 773 80.
38. Peters WA III. Liu PY Barrett RJ et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol 2000 18 1606 13.
39. Common Toxicity Criteria Manual Version 2.0, Cancer Therapy Evaluation Program. Available at http://ctep.info.nih.gov. Accessed 1999.
40. Moore DH McQuesson RP Blessing JA et al. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecology Oncology Group study [abstract]. Proc Am Soc Clin Oncol 2001 20 201a. Abstract 803.
41. Verschraegen CF Kavanagh JK Loyer E et al. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 2001 92 2327 33.
42. Von Pawel J von Roemeling R Gatzemeier U et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000 8 1351 9.
43. Rischin D Peters L Hicks R et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001 19 535 42.
44. Treat J Johnson E Langer C et al. Tirapazamine with cisplatin in patients with advanced non-small-cell cancer: a phase II study. J Clin Oncol 1998 16 3524 7.
45. Aghajanian C Brown C O'Flaherty C et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 1997 67 127 30.
46. Shulman LN Buswell L Riese N et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 1999 44 349 53.
47. Lee DJ Trotti A Spencer S et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int J Radiat Oncol Biol Phys 1998 42 811 5.
48. Craighead PS Pearcey R Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000 48 791 5.
49. Masunaga SI Ono K Suzuki M et al. Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells. Int J Radiat Oncol Biol Phys 2001 50 1063 72.
50. Weitman S Mangold G Marty J et al. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 1999 43 402 8.